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After establishing the benign nature of a gastric ulcer, the treatment is primari-
ly medical. This medical therapy is aimed to alleviate symptoms, to heal the
ulcer and to prevent relapses. Based on the history ofnon-steroidal anti-inflam-
matory drugs (NSAIDs) and the Helicobacter pylori-status, gastric ulcer
patients can be divided into four categories (1) H. pylori positive plus NSAID-
use, (2) H. pylori positive without NSAID use, (3) NSAID use with negative H.
pylori-status, (4) Negative H. pylori-status and no NSAID use.
Patients taking NSAIDs should stop this therapy if possible. Patients with gas-
tric H. pylori infection should be treated by a regimen of a proton pump
inhibitor with at least two appropriate antibiotics. This treatment will result in
early alleviation of symptoms, rapid healing of the ulcer and prophylaxis of
ulcer relapse. In patients with gastric ulcer who cannot stop NSAIDs, mainte-
nance therapy with prostaglandins or potent antisecretory drugs should be con-
sidered. The few patients with gastric ulcer who do not take NSAIDs and do not
have gastric H. pylori infection should be treated by antisecretory drugs, and
they should be carefully followed endoscopically to exclude malignant (carci-
noma, lymphoma) or non-peptic (Crohn's disease) disease. All patients with
gastric ulcer should be re-endoscoped to verify complete ulcer healing. Surgery
may be considered in gastric ulcer patients with complications, in those with
severe dysplasia ofthe gastric mucosa, and in those who are not able or willing
to take the medication.
INTRODUCTION
Histamine-2 receptor antagonists (H2RAs)b have been the mainstay of treatment of
gastric ulcer for many years [1]. These compounds have proved to be more effective than
antacids without relevant side-effects. H2RAs not only accelerate healing of gastric ulcer
but also prevent recurrences when used as prophylactic maintenance therapy [1, 2].
However, an analysis from Scandinavia showed that even between 1980 and 1990, about
one-third of gastric ulcer patients were burdened by their disease [3]. Recent develop-
ments have challenged the primacy ofH2RA in the treatment ofpeptic lesions. First, the
development of proton pump inhibitors with potent and long-acting antisecretory effects
has led to higher healing rates than those obtained with H2RAs [4, 5]. Second, the dis-
covery ofthe role ofHelicobacterpylori infection has warranted antimicrobial therapy as
the logical approach to gastric ulcerdisease [6, 7]. Third, there is increasing interest in the
importance of non-steroidal anti-inflammatory drugs (NSAIDs) in the pathogenesis of
gastric ulcer and in the possibility ofprevention with prostaglandin analogues [8, 9, 10].
Not only antisecretory drugs but also compounds that do not interfere with gastric
acid secretion have been shown to accelerate gastric ulcer healing when compared with
placebo treatment [ 1]. These so-called gastric protective agents comprise carbenoxolone,
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sucralfate, colloidal bismuth compounds and prostaglandin analogues. Furthermore, pro-
kinetics such as cisapride have been studied in the therapy of gastric ulcer [12]. However,
none ofthese drugs is superior to H2RAs in healing gastric ulcer and alleviating its symp-
toms [13].
ANTISECRETORY THERAPY IN GASTRIC ULCER
Meta-analysis of various antisecretory therapies for gastric ulcer has shown that there
are three primary determinants of gastric ulcer healing: (1) the duration of treatment, (2)
the degree of acid suppression and (3) the duration of acid suppression over the 24-hour
period [14]. The duration of treatment appears to be the most important single determi-
nant of gastric ulcer healing. Maintaining the gastric pH above 3 for 18 hours daily pre-
dicts healing in 100 percent of gastric ulcers at eight weeks, while such a degree of acid
suppression will heal all duodenal ulcers within four weeks [1, 14]. Thus, gastric ulcers
require longer antisecretory therapy than duodenal ulcers.
The importance of the degree and duration of suppression of gastric acid has been
clinically demonstrated in several studies comparing proton pump inhibitors with H2RAs.
In a large multicentral study of 602 patients with gastric ulcer, both omeprazole 20 mg
every morning and omeprazole 40 mg every morning induced significantly higher healing
rates at four weeks (69 percent and 80 percent) and eight weeks (89 percent and 96 per-
cent) than ranitidine 150 mg twice daily (59 percent and 85 percent at four and eight
weeks) [15]. Similar high healing rates were obtained with other proton pump inhibitors.
With lansoprazole in doses of 15, 30 and 60 mg every morning, healing rates of gastric
ulcer were 65 percent, 58 percent and 53 percent at four weeks and 92 percent, 97 percent
and 93 percent at eight weeks, respectively [16]. The overall healing rates of gastric ulcer
with pantoprazole were 84 percent and 97 percent at four and eight weeks, respectively
[5]. When compared to H2RAs, proton pump inhibitors tend to give slightly faster symp-
tom relief but the difference only rarely achieves statistical significance [5, 15].
Antisecretory agents are also efficacious in the prophylaxis of gastric ulcer. This pre-
ventive effect has mainly been studied using maintenance therapy with ranitidine. In a ret-
rospective study on patients taking 150 or 300 mg/day ranitidine as maintenance treatment
for gastric ulcer prophylaxis, the cumulative remission rates were 97 percent after one
year, 94 percent after two years, 90 percent after three years, 79 percent after four and five
years [2]. However, since the recognition of the important role ofH. pylori eradication in
prevention of peptic ulcer, maintenance therapy for the prevention of gastric ulcer is like-
ly to be replaced by H. pylori eradication regimens in the near future.
HELICOBACTER PYLORI ERADICATION IN GASTRIC ULCER
Prevalence ofH. pylori in gastric ulcer
It has been known for long time that gastric ulcer is often accompanied by chronic
gastritis. Prostaglandin deficiency secondary to this gastritis may contribute to the devel-
opment ofgastric ulcer despite the absence ofgastric acid hypersecretion in this condition
[17]. In fact, most patients with benign gastric ulcer have normal or low gastric acid secre-
tion. Gastric H. pylori infection may play a crucial role in the pathogenesis of the chron-
ic inflammation ofthe gastric mucosa often found in gastric ulcer patients [18]. In the past
10 years, a large number of studies have been performed to determine the prevalence of
H. pylori infection in gastric ulcer disease. In an analysis of 25 studies comprising 1395
patients with gastric ulcer, the prevalences ofH. pylori ranged from 44 to 100 percent with
an average of 84 percent [19]. In four of the studies, which comprised a total of 235
patients, the prevalence of H. pylori positivity in gastric ulcer was even100 percent The
failure to find H. pylori positivity in all gastric patients may be related to the inclusion of
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gastric ulcer due to NSAIDs or malignancy or to the low sensitivity ofthe biopsy test for
H. pylori [19].
Gastric ulcer healing in H. pylori-positive patients
Several therapeutic regimens have been developed to eradicate H. pylori from the
stomach. The optimal regimen will result in rapid gastric ulcer healing, fast pain reliefand
prevention of ulcer recurrences. The H. pylori status does not seem to influence the heal-
ing rate of gastric ulcer when treated with H2RAs. After 12 weeks of therapy with 800
mg/day cimetidine, 67 of 77 H. pylori-positive (87 percent) and 16 of 18 H. pylori-nega-
tive (89 percent) gastric ulcers were healed [20]. However, H. pylori eradication appears
to accelerate gastric ulcer healing. Labenz et al. treated a total of 83 patients presenting
with H. pylori-positive gastric ulcer with omeprazole and antibiotics [21]. At endoscopy
after six weeks, gastric ulcer healing was higher in the patients in whom H. pylori was
eradicated (85 percent) than in those with persistent H. pylori infection (60 percent).
Similar results were obtained by Seppala et al. who treated 210 gastric ulcer patients with
either colloidal bismuth subcitrate, or bismuth plus metronidazole orranitidine [22]. Atre-
endoscopy after 12 weeks, 32 of35 (91 percent) ofH. pylori-negative compared to 130 of
175 (74 percent) of H. pylori-positive patients had their gastric ulcer healed. Sung et al.
compared triple therapy consisting of bismuth subcitrate, tetracycline and metronidazole
with omeprazole in patients with H. pylori positive gastric ulcer [23]. Endoscopy at five
weeks showed complete healing of the ulcers in 84 percent on triple therapy and 73 per-
cent on omeprazole. However, the patients treated by omeprazole had experienced less
days with pain than the patients treated by triple therapy both in the first week (1.9 + 2.6
vs. 3.6± 3.0; p < .005) and in week two through five (4.4 +8.7 vs 7.6 +9.5; p = .09) [23].
Thus, the combination of a proton pump inhibitor and at least two antibiotics seems
presently to be the preferred therapy for H. pylorn positive gastric ulcer, since this regimen
is likely to result in early pain relief and successful H. pylori eradication.
Prevention ofH. pylori-positive gastric ulcers
As mentioned earlier, maintenance therapy with ranitidine prevents relapse of gastric
ulcer in the majority ofpatients [2]. In an open study with 150 or 300 mg/day ranitidine,
the proportion of patients remaining free from symptomatic recurrence was 97 percent
after one year and 79 percent after five years [2]. However, in a placebo-controlled study
on 12-month maintenance therapy with 150mgranitidine at night, only 64 percent ofthose
on ranitidine and 24 percent ofthose on placebo were free from gastric ulcer relapse [24].
Thus, despite maintenance therapy with ranitidine, about one-third of the patients had
symptomatic or asymptomatic recurrences of gastric ulcer within one year. The recogni-
tion of the association ofH. pylori infection with gastritis and peptic ulcer has prompted
several studies to be performed in order to determine whether H. pylori eradication pre-
vents relapse of gastric ulcer. Although the follow-up period was usually limited to one
year at the most, several studies have confirmed the importance of H. pylori eradication
therapy forprevention ofgastric ulcer relapse. Graham et al. studied 15 patients with gas-
tric ulcer treated with ranitidine plus triple therapy (bismuth subsalicylate, tetracycline and
metronidazole) and 11 gastric ulcer patients treated with ranitidine alone [25]. The life
table probability ofulcer recurrence one yearafter ulcerhealing was significantly lower in
the patients who had received ranitidine plus triple therapy (13 percent) than in those who
had been treated by ranitidine alone (74 percent). Similarresults were obtained by Sung et
al. who compared triple therapy (bismuth subcitrate, tetracycline and metronidazole) with
omeprazole [23]. One year after treatment, recurrent gastric ulcers were detected in one of
22 (5 percent) patients in the triple therapy group and 12 of23 (52 percent) patients in the
omeprazole group. Bayerdorffer et al. treated a total of 102 gastric ulcer patients with
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either triple therapy (bismuth subsalicylate, amoxicilline and tinidazole) or omeprazole
[26]. The 12-month gastric ulcer relapse rate was 51 percent in the patients who had
received omeprazole compared to three percent in those who had been treated by triple
therapy. In all of the above-mentioned studies, there was a striking relation between H.
pylori eradication and absence ofgastric ulcer recurrence. This relationship was confirmed
by studies in which gastric ulcer patients treated by H. pylori eradication therapy regimens
were divided into those with successful H. pylori eradication and those in whom the H.
pylori eradication regimen had failed. Labenz et al. reported a one-year gastric ulcer recur-
rence rate of 58 percent (10/18) in patients with H. pylori persistence compared to three
percent (1/32) in patients in whom H. pylori was eradicated from the stomach [21]. Similar
results were reported by Seppala et al. who reported a one-year recurrence rate of 47 per-
cent (60/128) and seven percent (2/29) in gastric ulcer patients after failed and successful
H. pylori eradication, respectively [22].
NON-STEROIDAL ANTI-INFLAMMATORY DRUGS AND GASTRIC ULCER
NSAIDs are generally accepted to play a pathogenetic role in the development ofgas-
tric ulcer in patients taking such drugs. These ulcers are suggested to be secondary to the
NSAID-induced reduction of gastric prostaglandins resulting in an impaired mucosal bar-
rier against aggressive luminal factors, such as acid or pepsin. Interestingly, gastric ulcer
may also occur during NSAID-use in patients with achlorhydria due to gastric atrophy
[27]. This finding may be important in understanding the limited role of antisecretory
drugs in NSAID-related gastric ulcer [28]. The contribution of H. pylori infection to the
pathogenesis of gastric ulcer in patients taking NSAIDs is a matter of debate.
In an endoscopic study of patients with rheumatoid arthritis, five of 81 [29] were
found to have a gastric ulcer. In the patients who were seropositive for H. pylori the gas-
tric ulcer rate was five percent (3/55) compared to eight percent (2/26) in H. pylori sero-
negative patients with rheumatoid arthritis. Thus, gastric ulcer may occur in both H.
pylori-positive and H. pylori-negative patients with rheumatoid arthritis. It has, however,
been claimed that NSAIDs induce gastric ulcer mainly in H. pylori carriers. In patients
with a history of NSAID use, H. pylori positivity was found in 21 of 27 (78 percent) gas-
tric ulcer patients compared to 13 of 38 (34 percent) patients without an ulcer [30].
Furthermore, a recent study in healthy volunteers showed that severe gastric damage
induced by NSAIDs was associated with H. pylori infection [31].
Since the ulcerogenic effect of NSAIDs has been well established, this therapy
should be discontinued in any patient with a gastric ulcer who is taking such drugs.
Continuing NSAID therapy is reported to lower the ulcer healing effect of antisecretory
drugs. For example, 32 percent and 53 percent of NSAID-users compared to 59 percent
and 85 percent of patients not taking NSAIDs had their gastric ulcer healed with 150 mg
twice daily ranitidine at four and eight weeks, respectively [15]. However, the percentage
of healed gastric ulcer with 40 mg/day omeprazole in patients receiving concurrent treat-
ment with NSAIDs (81 percent at four weeks and 95 percent at eight weeks) was not dif-
ferent from that in patients who did not take NSAIDs (80 percent at four weeks and 96
percent at eight weeks) [15]. Thus, in patients who need continuous NSAID-therapy,
powerful acid inhibitory therapy is required to heal gastric ulcer. It has not yet been estab-
lished whether H. pylori eradication therapy accelerates gastric ulcer healing during con-
tinuous NSAID therapy. Clinically it is very difficult to determine whether a gastric ulcer
in an H. pylori-positive patient with a history of NSAID use is related to the NSAID use,
to the H. pylori-associated gastritis or to the combination of both factors. Since H. pylori
eradication therapy largely prevents gastric ulcer recurrences, it seems logical to apply
this therapy also to H. pylori positive gastric ulcer patients with chronic NSAID use.
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However, the prophylactic effect of H. pylori eradication therapy in patients on continu-
ing NSAID treatment has yet to be determined.
H. pylori-negative patients on chronic NSAID therapy who have ahistory ofNSAID-
induced gastric ulcer are candidates for long-term prophylactic therapy. The efficacy of
acid inhibitory therapy in the prevention ofgastric ulcer in patients taking NSAIDs is lim-
ited. Preliminary studies suggest that powerful acid inhibitory therapy with high-dose
H2RAs or proton pump inhibitors may be beneficial in such patients [32, 33]. Another
approach is the long-term administration ofprostaglandin analogues. Several studies have
shown that the prostaglandin analogue misoprostol lowers the relapse rate ofgastric ulcer
in patients on chronic NSAID-therapy [8-10, 34]. However, side-effects (abdominal
cramps, diarrhea) occur rather frequently and may hamper the application ofthis class of
compounds.
CONCLUSION
The recent appreciation of the importance of H. pylori infection and of NSAID use
has changed the medical management ofpatients with a gastric ulcer. By far the majority
ofpatients will be effectively managed by one of the modalities ofdrug therapy. Surgery
is to be restricted to gastric ulcer patients with complications, severe dysplasia and those
who are not able or willing to take the medication.
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